What is the success rate of stem cell therapy for Multiple Sclerosis?
No single success rate covers AHSCT, MSCs or neural-cell products. Review the exact population, comparator, relapse activity, MRI outcomes, disability measures, treatment-related mortality, adverse events and duration. Stabilisation is not the same as repair.
What the evidence shows for Multiple Sclerosis
AHSCT has been studied for selected people with highly active inflammatory MS, while its risks include those of intensive conditioning and immune suppression. NIH describes AHSCT as an experimental approach being compared with best available biologic therapy in severe relapsing MS. MSC, neural-cell and exosome proposals have different and generally earlier evidence. See the NINDS MS research overview and verify the exact protocol.
Am I a candidate? → · Multiple Sclerosis: full overview → · Multiple Sclerosis cost → · Cost →
Evidence checked against ISSCR, FDA and EMA guidance. See our editorial standards. This is information, not medical advice. Educational information, not medical advice; figures indicative.
Sources & further reading
More on this condition
- Multiple Sclerosis: cell-therapy evidence and registered trials
- How much does stem cell therapy for Multiple Sclerosis cost? (2026)
- Multiple Sclerosis stem cell therapy — your questions answered (2026)
- Multiple Sclerosis: cell-therapy evidence by therapy class
- MSC vs HSCT for Multiple Sclerosis: what the registries show